drugset

drugset / Trial / NCT00373906

Velcade in MALT Lymphoma Patients

NCT00373906 ↗

Phase 2 Completed 16 enrolled Medical University of Vienna

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.

Timeline

Start: —
Primary completion: —
Completion: —

Publications

Troch M, Jonak C, Mullauer L, Puspok A, Formanek M, Hauff W, Zielinski CC, Chott A, Raderer M. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009 May;94(5):738-42. doi: 10.3324/haematol.2008.001537. Epub 2009 Mar 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.5 mg/m2	Intravenous

Indications